TUCSON, AZ--(Marketwire - June 08, 2011) -
CDEX Inc. (OTCBB: CEXI
), a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced today its ID2™ Product line has successfully passed independent testing to verify conformance to the protection requirements of the European Economic Area (EEA) gaining full CE certification. The CE approval means that the entire European market is now open for the company to commercially distribute the ID2 Meth Scanner and Pocket ID2 Illicit Drug Scanner. The company will begin accelerating marketing efforts with its international distribution partners.
The CE Marking Label and the CE Declaration of Conformity are essential for product import and distribution into the European Union (EU) in compliance with all EU Regulations.
"We are very pleased to gain full CE certification allowing our current distribution partners to begin marketing our ID2 products in Europe. Strong demand exists for our innovative technology which is designed for use in law enforcement, correctional facilities and other applications where definitive and immediate results are crucial. Our ID2 meth scanner and ID2 Pocket scanner tests results are instantaneous, with the Pocket ID2 being completely non-destructive, and the ID2 meth scanner requiring a simple 'mining' process for sample gathering. Both products test for the presence of methamphetamine without the user having to touch the scanned surfaces, thus minimizing exposure to personnel and preserving the integrity of the sample substance for future analysis," stated Jeff Brumfield, chairman and chief executive officer of CDEX. "Now we can provide a safe and effective solution to European agencies to detect methamphetamines and soon other illicit drugs such as cocaine. We have received strong interest from our international distributors to gain CE approval for the ID2 product line and expect to begin shipping orders over the next 60 days."
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.
Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.